![iito] Business Intelligence Logo](https://res.cloudinary.com/zoominfo-images/image/upload/w_120,h_120,c_fit/life-sciences-europe.com){kind=small}
Epsilogen
Manufacturing · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Waterfront Arc West London Manbre Hammer...Phone Number
+44 2036577612Website
www.epsilogen.comRevenue
$11.5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Epsilogen
Epsilogen is a pioneering company specializing in pan-isotype antibody therapeutics for cancer treatment, focusing on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead product, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, targeting folate receptors in platinum-resistant ovarian cancer patients. The company aims to optimize immune responses by matching antibody isotypes to specific cancers and combining them to enhance anti-cancer potential. Epsilogen's innovative approach positions it as a leader in the development of novel cancer therapies.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Epsilogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Epsilogen is spiking on competitors!
Funding: Get notified immidiatlly once Epsilogen has new funding data
Check if Epsilogen has recently received funding, and reach out quickly before it becomes old news!
Epsilogen, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Epsilogen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Epsilogen
Earning: See what the market has to say on Epsilogen recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Epsilogen launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Epsilogen as Masked Content
Find more new buyers
Compare Similar Companies to Epsilogen
Compare insights from companies similar to Epsilogen, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Epsilogen
$11.5M
11-50
Private
$67.8M
2017
N/A
Company Profile Activity
Activity Insights
Epsilogen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Epsilogen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Epsilogen.
Epsilogen financials insights
Gather financial insights about Epsilogen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Series A
$6.3M
2020
Other Financing Round
$3.9M
2024
Series B
$57.6M
Epsilogen Tech Stack
A closer look at the technologies used by Epsilogen
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Events, Engineering, Sales, Bioengineering, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Operations
New Hire
Executive Move
Executive Moves, New Hire
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Open Position
Epsilogen News & Media
Epsilogen names Cristina Oliva as CMO | The Pharmaletter
UK-based developer of novel immunoglobulin E (IgE) antibodies to treat cancer, Epsilogen, today announced the appointment of Cristina Oliva as chief medical officer (CMO). Dr Oliva is a board-certified oncologist and brings global experience across all stages of oncology drug development.Epsilogen Announces Acquisition of TigaTx, Inc. to Create World's Leading Pan-Isotype ...
Highlights The acquisition combines IgA antibody assets and expertise of Boston-based TigaTx with Epsilogen’s assets and expertise in IgE to create the world’s leading pan-isotype cancer antibody company Allows selection of the most appropriate antibody isotype for a given cancer, applying the unique mechanisms of action for each: IgA activates neutrophils, a potent and highly abundant immune effector cell IgE activates T cells and macrophages to warm up the tumour microenvironment (TME) FacilitEpsilogen Announces Initiation of Phase Ib Trial of MOv18 IgE
LONDON--(BUSINESS WIRE)--Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces that it has commenced a Phase Ib study evaluating MOv18 IgE in patients with platinum-resistant ovarian cancer (PROC). The Phase Ib, open-label, dose escalation and expansion trial (NCT06547840) will enrol 45 patients with PROC whose disease has progressed after no more than four lines of prior therapy. The trial will assess the safety, tolerability andEpsilogen Completes £12.5 Million Series B Financing Expansion
LONDON--(BUSINESS WIRE)--Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the completion of a £12.5 million Series B expansion financing bringing the Series B total to £43.25 million. This financing will fund the delivery of clinical Proof of Concept for lead asset MOv18 IgE in a phase Ib trial featuring platinum-resistant ovarian cancer (PROC) as well as further development of the company’s IgE-based pipeline. The financing was
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Epsilogen
Sign Up For FreeTo access detailed company insights
Epsilogen is a pioneering company specializing in pan-isotype antibody therapeutics for cancer treatment, focusing on immunoglobulin IgE, IgA, and IgG-based therapies. Their lead product, MOv18 IgE, is the first therapeutic IgE antibody in clinical trials, targeting folate receptors in platinum-resistant ovarian cancer patients. The company aims to... Read More
